Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,615 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04931992 | Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.(MOLAM) | unknown | — | 100 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2021 | clinicaltrials |
| NCT04906031 | Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations | unknown | Phase 2 | 5 | First Affiliated Hospital of Jinan UniversityOTHER | 1 | Jun 9, 2021 |
| clinicaltrials |
| NCT04920500 | Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients | unknown | N/A | 16 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04069208 | IA14 Induction in Young Acute Myeloid Leukemia | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT01894477 | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | unknown | Phase 2 | 102 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT04762485 | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04904237 | Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. | unknown | Phase 2 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT02530619 | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia | unknown | N/A | 26 | Northwestern UniversityOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT03795779 | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT04884984 | Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT03080766 | The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype | unknown | Phase 2 | 20 | The University of Hong KongOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04818619 | TIGIT in Patients With Chronic Myeloid Leukemia | unknown | — | 65 | Assiut UniversityOTHER | 0 | Mar 29, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01296178 | PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years | unknown | N/A | 200 | PETHEMA FoundationOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT02607059 | Epidemiologic Registry PETHEMA LMA 2015 | unknown | — | 500 | PETHEMA FoundationOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04806659 | A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia | unknown | Phase 1 | 41 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Mar 19, 2021 | clinicaltrials |
| NCT04692948 | TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia | unknown | N/A | 5 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 8, 2021 | clinicaltrials |
| NCT04747002 | Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients. | unknown | Phase 2 | 100 | Osaka UniversityOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04766840 | Donor-derived CAR-T Cells in the Treatment of AML Patients | unknown | Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2021 | clinicaltrials |
| NCT03662724 | Venetoclax Registry(VENreg) | unknown | — | 100 | Hannover Medical SchoolOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT03096496 | Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy | unknown | — | 161 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04743115 | A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS | unknown | Phase 1 | 66 | Shanghai Bensen Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 8, 2021 | clinicaltrials |
| NCT04709731 | Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia(CarPAs) | unknown | Phase 2 | 50 | Associazione Italiana Pazienti Leucemia Mieloide CronicaOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04708444 | Prognostic Value of CD318 in AML at Assiut University Hospital. | unknown | — | 100 | Shimaa Arafa IbrahimOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT03955848 | INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS(NKAML) | unknown | N/A | 80 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04701229 | Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes(SMD-RMB22) | unknown | — | 100 | University Hospital, BrestOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00600860 | A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes(EUMDS) | unknown | — | 4,000 | Radboud University Medical CenterOTHER | 18 | Dec 30, 2020 | clinicaltrials |
| NCT03530085 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04254640 | Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03135054 | Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD | unknown | Phase 2 | 40 | The University of Hong KongOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04636918 | Ikervis for DED Due to GVHD Post Allo-HSCT(Ikervis) | unknown | Phase 4 | 40 | Singapore Eye Research InstituteOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02172365 | Allogeneic SCT for CML, TKI Failure After TKI Failure | unknown | — | 350 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT01064570 | AIDA 2000 Guidelines | unknown | Phase 2 | 600 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03083054 | Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | University of Campinas, BrazilOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT04578847 | A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)(READIT) | unknown | Phase 2 | 100 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04221971 | NK Cell Infusion for Patients With Acute Myeloid Leukemia | unknown | Phase 1 | 10 | Peking University People's HospitalOTHER | 1 | Oct 1, 2020 | clinicaltrials |
| NCT04373395 | Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | N/A | 65 | Zhejiang UniversityOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04454580 | Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy | unknown | — | 15 | Ospedale Maggiore Di TriesteOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02381379 | Malaysia Stop Tyrosine Kinase Inhibitor Trial(MSIT) | unknown | Phase 3 | 118 | Ministry of Health, MalaysiaOTHER_GOV | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04541277 | Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy | unknown | Phase 2 | 55 | Chinese PLA General HospitalOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04240600 | Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay(HEMVEF) | unknown | N/A | 74 | Hospital General de MexicoOTHER_GOV | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04527666 | Anticoagulation in Gastroesophageal Varices and JAK2 Mutation | unknown | — | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 27, 2020 | clinicaltrials |
| NCT04525768 | Gastroesophageal Varices in Cavernoma | unknown | — | 80 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT04517175 | Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics? | unknown | — | 300 | Maastricht UniversityOTHER | 0 | Aug 18, 2020 | clinicaltrials |
| NCT04505995 | Azacitidine and Homoharringtonine in JMML | unknown | N/A | 30 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04209712 | Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease | unknown | Early Phase 1 | 6 | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaINDUSTRY | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04288739 | Immunophenotyping and Xist Gene in AML(Xist) | unknown | — | 65 | Assiut UniversityOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT04272957 | A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms | unknown | Phase 1 | 75 | Hutchison Medipharma LimitedINDUSTRY | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04392310 | Outcomes of Acute Myeloid Leukemia Patients | unknown | — | 50 | Assiut UniversityOTHER | 0 | May 18, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2021source: clinicaltrials